TISSUE FACTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR EXPRESSION IN THE DIFFERENTIATION OF MYELOID LEUKEMIC-CELLS

被引:0
作者
DICKINSON, JL [1 ]
ANTALIS, TM [1 ]
机构
[1] QUEENSLAND INST MED RES,QUEENSLAND CANC FUND,ONCOL RES UNIT,BANCROFT CTR,300 HERSTON ROAD,BRISBANE,QLD 4029,AUSTRALIA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Disturbances in the regulation of the balance between the fibrinolytic and procoagulant properties of leukemic cells may contribute to the coagulopathy of acute leukemia. The coagulant response to a number of stimuli is regulated by the expression of tissue factor, but the role of the plasminogen activator inhibitors, PAI-1 and PAI-2, in contributing to the net coagulant response is not known. In this study, we have examined the production of these proteins by cultured myeloid leukemic cells arrested at different stages of differentiation. Northern blot analysis showed time-dependent and differential production of mRNA for PAI-2 and tissue factor, and to a much lesser extent, PAI-1, in response to the differentiating agent, 12-phorbol-13-myristate acetate. The capacity to synthesize PAI-2 appeared to be related to the stage of myeloid cell differentiation. Examination of the gene products by immunoblot analysis demonstrated multiple forms of PAI-2 in all myeloid cells examined. In addition, a common characteristic of all the myeloid cells was the production of a high molecular weight species of tissue factor which may be a secreted form unique to leukemic cells. Taken together, the findings demonstrate that myeloid leukemic cells are capable of generating a multicomponent coagulant response.
引用
收藏
页码:864 / 871
页数:8
相关论文
共 45 条
[1]   CLONING AND EXPRESSION OF A CDNA CODING FOR A HUMAN MONOCYTE-DERIVED PLASMINOGEN-ACTIVATOR INHIBITOR [J].
ANTALIS, TM ;
CLARK, MA ;
BARNES, T ;
LEHRBACH, PR ;
DEVINE, PL ;
SCHEVZOV, G ;
GOSS, NH ;
STEPHENS, RW ;
TOLSTOSHEV, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (04) :985-989
[2]  
ANTALIS TM, 1992, EUR J BIOCHEM, V205, P303
[3]   CHANGES IN PLASMA-LEVELS OF TISSUE-PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX AND ACTIVE PLASMINOGEN-ACTIVATOR INHIBITOR IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION [J].
ASAKURA, H ;
JOKAJI, H ;
SAITO, M ;
UOTANI, C ;
KUMABASHIRI, I ;
MORISHITA, E ;
YAMAZAKI, M ;
MATSUDA, T .
AMERICAN JOURNAL OF HEMATOLOGY, 1991, 36 (03) :176-183
[4]   THE COMMON MEDIATOR OF SHOCK, CACHEXIA, AND TUMOR NECROSIS [J].
BEUTLER, B ;
CERAMI, A .
ADVANCES IN IMMUNOLOGY, 1988, 42 :213-231
[5]   TISSUE FACTOR APOPROTEIN - INTRACELLULAR-TRANSPORT AND EXPRESSION IN SHED MEMBRANE-VESICLES [J].
BONA, R ;
LEE, E ;
RICKLES, F .
THROMBOSIS RESEARCH, 1987, 48 (04) :487-500
[6]   CELL-LINES DERIVED FROM A HUMAN MYELOMONOCYTIC LEUKEMIA [J].
BRADLEY, TR ;
PILKINGTON, G ;
GARSON, M ;
HODGSON, GS ;
KRAFT, N .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (04) :595-604
[7]  
BRATT G, 1985, SCAND J HAEMATOL, V34, P332
[8]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[9]   CONTINUOUS GROWTH AND DIFFERENTIATION OF HUMAN MYELOID LEUKEMIC-CELLS IN SUSPENSION CULTURE [J].
COLLINS, SJ ;
GALLO, RC ;
GALLAGHER, RE .
NATURE, 1977, 270 (5635) :347-349
[10]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266